nodes	percent_of_prediction	percent_of_DWPC	metapath
Sorafenib—Vismodegib—skin cancer	0.494	1	CrCtD
Sorafenib—BRAF—skin cancer	0.152	1	CbGaD
Sorafenib—RAF1—Vemurafenib—skin cancer	0.0753	0.337	CbGbCtD
Sorafenib—BRAF—Vemurafenib—skin cancer	0.063	0.282	CbGbCtD
Sorafenib—ABCG2—Vismodegib—skin cancer	0.00904	0.0404	CbGbCtD
Sorafenib—ABCG2—Vemurafenib—skin cancer	0.00715	0.032	CbGbCtD
Sorafenib—ABCC4—Fluorouracil—skin cancer	0.00597	0.0267	CbGbCtD
Sorafenib—CYP1A2—Imiquimod—skin cancer	0.00538	0.024	CbGbCtD
Sorafenib—CYP2C8—Vismodegib—skin cancer	0.00482	0.0215	CbGbCtD
Sorafenib—ABCG2—Dactinomycin—skin cancer	0.00475	0.0212	CbGbCtD
Sorafenib—CYP2C19—Vismodegib—skin cancer	0.00404	0.0181	CbGbCtD
Sorafenib—CYP2C9—Vismodegib—skin cancer	0.00336	0.015	CbGbCtD
Sorafenib—ABCB1—Vismodegib—skin cancer	0.00326	0.0146	CbGbCtD
Sorafenib—ABCG2—Fluorouracil—skin cancer	0.00321	0.0144	CbGbCtD
Sorafenib—CYP1A2—Vemurafenib—skin cancer	0.00295	0.0132	CbGbCtD
Sorafenib—CYP3A4—Temozolomide—skin cancer	0.00282	0.0126	CbGbCtD
Sorafenib—CYP3A4—Imiquimod—skin cancer	0.00282	0.0126	CbGbCtD
Sorafenib—ABCC2—Docetaxel—skin cancer	0.00271	0.0121	CbGbCtD
Sorafenib—ABCG2—Docetaxel—skin cancer	0.00245	0.011	CbGbCtD
Sorafenib—CYP2D6—Vemurafenib—skin cancer	0.00243	0.0109	CbGbCtD
Sorafenib—CYP1A2—Dacarbazine—skin cancer	0.00226	0.0101	CbGbCtD
Sorafenib—CYP3A4—Vismodegib—skin cancer	0.00195	0.00873	CbGbCtD
Sorafenib—CYP3A7—Docetaxel—skin cancer	0.00181	0.0081	CbGbCtD
Sorafenib—CYP3A7-CYP3A51P—Docetaxel—skin cancer	0.00181	0.0081	CbGbCtD
Sorafenib—ABCB1—Dactinomycin—skin cancer	0.00171	0.00766	CbGbCtD
Sorafenib—CYP2C8—Fluorouracil—skin cancer	0.00171	0.00765	CbGbCtD
Sorafenib—CYP3A4—Vemurafenib—skin cancer	0.00154	0.0069	CbGbCtD
Sorafenib—CYP3A5—Docetaxel—skin cancer	0.00136	0.00607	CbGbCtD
Sorafenib—CYP1A2—Fluorouracil—skin cancer	0.00132	0.00592	CbGbCtD
Sorafenib—Vismodegib—SHH—skin cancer	0.00131	0.512	CrCbGaD
Sorafenib—CYP2C9—Fluorouracil—skin cancer	0.00119	0.00533	CbGbCtD
Sorafenib—ABCB1—Docetaxel—skin cancer	0.000884	0.00395	CbGbCtD
Sorafenib—PDGFRA—penis—skin cancer	0.000809	0.0257	CbGeAlD
Sorafenib—Vismodegib—SMO—skin cancer	0.000755	0.294	CrCbGaD
Sorafenib—KDR—hindlimb—skin cancer	0.000551	0.0175	CbGeAlD
Sorafenib—CYP3A4—Docetaxel—skin cancer	0.00053	0.00237	CbGbCtD
Sorafenib—TIE1—endothelium—skin cancer	0.000525	0.0167	CbGeAlD
Sorafenib—Regorafenib—BRAF—skin cancer	0.0005	0.195	CrCbGaD
Sorafenib—TIE1—blood vessel—skin cancer	0.000485	0.0154	CbGeAlD
Sorafenib—KDR—appendage—skin cancer	0.000473	0.015	CbGeAlD
Sorafenib—CDKL3—female reproductive system—skin cancer	0.000461	0.0146	CbGeAlD
Sorafenib—FLT4—endothelium—skin cancer	0.000434	0.0138	CbGeAlD
Sorafenib—CDKL2—female reproductive system—skin cancer	0.000422	0.0134	CbGeAlD
Sorafenib—FLT4—blood vessel—skin cancer	0.0004	0.0127	CbGeAlD
Sorafenib—MKNK2—hair follicle—skin cancer	0.000386	0.0123	CbGeAlD
Sorafenib—ZAK—nipple—skin cancer	0.000383	0.0122	CbGeAlD
Sorafenib—MKNK1—hair follicle—skin cancer	0.000382	0.0121	CbGeAlD
Sorafenib—MAPK15—female reproductive system—skin cancer	0.00038	0.0121	CbGeAlD
Sorafenib—CDKL2—head—skin cancer	0.000353	0.0112	CbGeAlD
Sorafenib—RALBP1—hair follicle—skin cancer	0.000349	0.0111	CbGeAlD
Sorafenib—KIT—skin epidermis—skin cancer	0.000349	0.0111	CbGeAlD
Sorafenib—FLT1—endothelium—skin cancer	0.000338	0.0107	CbGeAlD
Sorafenib—RAF1—hair follicle—skin cancer	0.00033	0.0105	CbGeAlD
Sorafenib—MAPK15—head—skin cancer	0.000317	0.0101	CbGeAlD
Sorafenib—CDK7—connective tissue—skin cancer	0.000314	0.00998	CbGeAlD
Sorafenib—FLT1—blood vessel—skin cancer	0.000311	0.00988	CbGeAlD
Sorafenib—KDR—endothelium—skin cancer	0.000285	0.00906	CbGeAlD
Sorafenib—MAP3K7—nipple—skin cancer	0.00027	0.00858	CbGeAlD
Sorafenib—HIPK3—connective tissue—skin cancer	0.000266	0.00844	CbGeAlD
Sorafenib—KDR—blood vessel—skin cancer	0.000263	0.00835	CbGeAlD
Sorafenib—MKNK2—nipple—skin cancer	0.000262	0.00832	CbGeAlD
Sorafenib—MKNK1—nipple—skin cancer	0.000259	0.00821	CbGeAlD
Sorafenib—HIPK4—female reproductive system—skin cancer	0.000256	0.00811	CbGeAlD
Sorafenib—KIT—endothelium—skin cancer	0.000253	0.00803	CbGeAlD
Sorafenib—RET—neck—skin cancer	0.000253	0.00803	CbGeAlD
Sorafenib—RALBP1—nipple—skin cancer	0.000237	0.00751	CbGeAlD
Sorafenib—TIE1—epithelium—skin cancer	0.000236	0.00749	CbGeAlD
Sorafenib—KIT—blood vessel—skin cancer	0.000233	0.0074	CbGeAlD
Sorafenib—CDK7—lymphoid tissue—skin cancer	0.00023	0.00729	CbGeAlD
Sorafenib—PDGFRB—blood vessel—skin cancer	0.000228	0.00723	CbGeAlD
Sorafenib—FLT3—connective tissue—skin cancer	0.000226	0.00717	CbGeAlD
Sorafenib—MAPK11—female reproductive system—skin cancer	0.000225	0.00715	CbGeAlD
Sorafenib—FLT1—nipple—skin cancer	0.000225	0.00714	CbGeAlD
Sorafenib—RAF1—nipple—skin cancer	0.000224	0.0071	CbGeAlD
Sorafenib—ZAK—mammalian vulva—skin cancer	0.000224	0.0071	CbGeAlD
Sorafenib—FLT1—neck—skin cancer	0.000223	0.00707	CbGeAlD
Sorafenib—EPHB6—nipple—skin cancer	0.000222	0.00706	CbGeAlD
Sorafenib—CDK7—female reproductive system—skin cancer	0.000222	0.00704	CbGeAlD
Sorafenib—RAF1—neck—skin cancer	0.000221	0.00703	CbGeAlD
Sorafenib—AURKC—female reproductive system—skin cancer	0.000218	0.00693	CbGeAlD
Sorafenib—EPHA6—female reproductive system—skin cancer	0.000202	0.00641	CbGeAlD
Sorafenib—ZAK—lymphoid tissue—skin cancer	0.000199	0.0063	CbGeAlD
Sorafenib—FLT4—epithelium—skin cancer	0.000195	0.00619	CbGeAlD
Sorafenib—ZAK—female reproductive system—skin cancer	0.000192	0.00608	CbGeAlD
Sorafenib—KDR—nipple—skin cancer	0.00019	0.00604	CbGeAlD
Sorafenib—MAP2K5—nipple—skin cancer	0.00019	0.00604	CbGeAlD
Sorafenib—KDR—neck—skin cancer	0.000188	0.00598	CbGeAlD
Sorafenib—MAPK11—head—skin cancer	0.000188	0.00597	CbGeAlD
Sorafenib—HIPK3—female reproductive system—skin cancer	0.000187	0.00595	CbGeAlD
Sorafenib—EPHX2—mammalian vulva—skin cancer	0.000187	0.00595	CbGeAlD
Sorafenib—MKNK2—connective tissue—skin cancer	0.000186	0.0059	CbGeAlD
Sorafenib—CSF1R—nipple—skin cancer	0.000186	0.00589	CbGeAlD
Sorafenib—CDK7—head—skin cancer	0.000185	0.00588	CbGeAlD
Sorafenib—MAP3K19—female reproductive system—skin cancer	0.000184	0.00583	CbGeAlD
Sorafenib—AURKC—head—skin cancer	0.000182	0.00579	CbGeAlD
Sorafenib—RET—connective tissue—skin cancer	0.000181	0.00575	CbGeAlD
Sorafenib—MKNK2—epithelium—skin cancer	0.000176	0.0056	CbGeAlD
Sorafenib—TIE1—female reproductive system—skin cancer	0.000175	0.00556	CbGeAlD
Sorafenib—RET—epithelium—skin cancer	0.000172	0.00546	CbGeAlD
Sorafenib—EPHA6—head—skin cancer	0.000169	0.00536	CbGeAlD
Sorafenib—KIT—nipple—skin cancer	0.000169	0.00535	CbGeAlD
Sorafenib—KIT—neck—skin cancer	0.000167	0.0053	CbGeAlD
Sorafenib—FGFR1—mammalian vulva—skin cancer	0.000167	0.00529	CbGeAlD
Sorafenib—FLT3—lymphoid tissue—skin cancer	0.000165	0.00525	CbGeAlD
Sorafenib—PDGFRB—nipple—skin cancer	0.000165	0.00523	CbGeAlD
Sorafenib—PDGFRB—neck—skin cancer	0.000163	0.00517	CbGeAlD
Sorafenib—ZAK—head—skin cancer	0.00016	0.00508	CbGeAlD
Sorafenib—FLT1—connective tissue—skin cancer	0.00016	0.00507	CbGeAlD
Sorafenib—FLT3—female reproductive system—skin cancer	0.000159	0.00506	CbGeAlD
Sorafenib—RAF1—connective tissue—skin cancer	0.000159	0.00504	CbGeAlD
Sorafenib—MAP3K7—mammalian vulva—skin cancer	0.000158	0.00501	CbGeAlD
Sorafenib—MAP3K19—head—skin cancer	0.000153	0.00487	CbGeAlD
Sorafenib—MKNK2—mammalian vulva—skin cancer	0.000153	0.00486	CbGeAlD
Sorafenib—FLT1—epithelium—skin cancer	0.000152	0.00481	CbGeAlD
Sorafenib—MKNK1—mammalian vulva—skin cancer	0.000151	0.0048	CbGeAlD
Sorafenib—RAF1—epithelium—skin cancer	0.000151	0.00478	CbGeAlD
Sorafenib—FLT4—lymphoid tissue—skin cancer	0.00015	0.00476	CbGeAlD
Sorafenib—PDGFRA—connective tissue—skin cancer	0.00015	0.00475	CbGeAlD
Sorafenib—TIE1—head—skin cancer	0.000146	0.00465	CbGeAlD
Sorafenib—FLT4—female reproductive system—skin cancer	0.000145	0.0046	CbGeAlD
Sorafenib—RAF1—skin of body—skin cancer	0.000143	0.00455	CbGeAlD
Sorafenib—EPHB6—skin of body—skin cancer	0.000142	0.00452	CbGeAlD
Sorafenib—RALBP1—mammalian vulva—skin cancer	0.000138	0.00439	CbGeAlD
Sorafenib—MKNK2—lymphoid tissue—skin cancer	0.000136	0.00431	CbGeAlD
Sorafenib—KDR—connective tissue—skin cancer	0.000135	0.00428	CbGeAlD
Sorafenib—MKNK1—lymphoid tissue—skin cancer	0.000134	0.00426	CbGeAlD
Sorafenib—RET—lymphoid tissue—skin cancer	0.000133	0.00421	CbGeAlD
Sorafenib—MAPK11—lymph node—skin cancer	0.000132	0.00418	CbGeAlD
Sorafenib—CSF1R—connective tissue—skin cancer	0.000132	0.00418	CbGeAlD
Sorafenib—FLT1—mammalian vulva—skin cancer	0.000131	0.00417	CbGeAlD
Sorafenib—MKNK2—female reproductive system—skin cancer	0.000131	0.00416	CbGeAlD
Sorafenib—RAF1—mammalian vulva—skin cancer	0.000131	0.00415	CbGeAlD
Sorafenib—EPHB6—mammalian vulva—skin cancer	0.00013	0.00412	CbGeAlD
Sorafenib—CDK7—lymph node—skin cancer	0.00013	0.00412	CbGeAlD
Sorafenib—MKNK1—female reproductive system—skin cancer	0.000129	0.00411	CbGeAlD
Sorafenib—TAOK2—lymph node—skin cancer	0.000129	0.00408	CbGeAlD
Sorafenib—KDR—epithelium—skin cancer	0.000128	0.00407	CbGeAlD
Sorafenib—AURKC—lymph node—skin cancer	0.000128	0.00405	CbGeAlD
Sorafenib—STK10—mammalian vulva—skin cancer	0.000124	0.00395	CbGeAlD
Sorafenib—FLT4—head—skin cancer	0.000121	0.00384	CbGeAlD
Sorafenib—KIT—connective tissue—skin cancer	0.00012	0.0038	CbGeAlD
Sorafenib—CSF1R—skin of body—skin cancer	0.000119	0.00377	CbGeAlD
Sorafenib—RALBP1—female reproductive system—skin cancer	0.000118	0.00376	CbGeAlD
Sorafenib—PDGFRB—connective tissue—skin cancer	0.000117	0.00371	CbGeAlD
Sorafenib—FLT1—lymphoid tissue—skin cancer	0.000117	0.0037	CbGeAlD
Sorafenib—RAF1—lymphoid tissue—skin cancer	0.000116	0.00368	CbGeAlD
Sorafenib—KIT—epithelium—skin cancer	0.000114	0.0036	CbGeAlD
Sorafenib—FLT1—female reproductive system—skin cancer	0.000113	0.00357	CbGeAlD
Sorafenib—ZAK—lymph node—skin cancer	0.000112	0.00356	CbGeAlD
Sorafenib—RAF1—female reproductive system—skin cancer	0.000112	0.00355	CbGeAlD
Sorafenib—MAP2K5—mammalian vulva—skin cancer	0.000111	0.00353	CbGeAlD
Sorafenib—KDR—mammalian vulva—skin cancer	0.000111	0.00353	CbGeAlD
Sorafenib—PDGFRB—epithelium—skin cancer	0.000111	0.00352	CbGeAlD
Sorafenib—STK10—lymphoid tissue—skin cancer	0.00011	0.00351	CbGeAlD
Sorafenib—HIPK3—lymph node—skin cancer	0.00011	0.00348	CbGeAlD
Sorafenib—MKNK2—head—skin cancer	0.000109	0.00348	CbGeAlD
Sorafenib—PDGFRA—lymphoid tissue—skin cancer	0.000109	0.00347	CbGeAlD
Sorafenib—CSF1R—mammalian vulva—skin cancer	0.000108	0.00344	CbGeAlD
Sorafenib—MKNK1—head—skin cancer	0.000108	0.00343	CbGeAlD
Sorafenib—KIT—skin of body—skin cancer	0.000108	0.00343	CbGeAlD
Sorafenib—RET—head—skin cancer	0.000107	0.00339	CbGeAlD
Sorafenib—STK10—female reproductive system—skin cancer	0.000107	0.00338	CbGeAlD
Sorafenib—PDGFRA—female reproductive system—skin cancer	0.000105	0.00335	CbGeAlD
Sorafenib—PDGFRB—skin of body—skin cancer	0.000105	0.00335	CbGeAlD
Sorafenib—TIE1—lymph node—skin cancer	0.000103	0.00325	CbGeAlD
Sorafenib—RALBP1—head—skin cancer	9.89e-05	0.00314	CbGeAlD
Sorafenib—KDR—lymphoid tissue—skin cancer	9.87e-05	0.00313	CbGeAlD
Sorafenib—KIT—mammalian vulva—skin cancer	9.85e-05	0.00313	CbGeAlD
Sorafenib—BRAF—lymph node—skin cancer	9.83e-05	0.00312	CbGeAlD
Sorafenib—CSF1R—lymphoid tissue—skin cancer	9.63e-05	0.00306	CbGeAlD
Sorafenib—PDGFRB—mammalian vulva—skin cancer	9.62e-05	0.00305	CbGeAlD
Sorafenib—KDR—female reproductive system—skin cancer	9.52e-05	0.00302	CbGeAlD
Sorafenib—MAP2K5—female reproductive system—skin cancer	9.52e-05	0.00302	CbGeAlD
Sorafenib—FLT1—head—skin cancer	9.41e-05	0.00299	CbGeAlD
Sorafenib—EPHX2—lymph node—skin cancer	9.39e-05	0.00298	CbGeAlD
Sorafenib—RAF1—head—skin cancer	9.35e-05	0.00297	CbGeAlD
Sorafenib—FLT3—lymph node—skin cancer	9.33e-05	0.00296	CbGeAlD
Sorafenib—EPHB6—head—skin cancer	9.3e-05	0.00295	CbGeAlD
Sorafenib—CSF1R—female reproductive system—skin cancer	9.29e-05	0.00295	CbGeAlD
Sorafenib—CYP1A2—nipple—skin cancer	8.91e-05	0.00283	CbGeAlD
Sorafenib—STK10—head—skin cancer	8.9e-05	0.00283	CbGeAlD
Sorafenib—PDGFRA—head—skin cancer	8.81e-05	0.0028	CbGeAlD
Sorafenib—KIT—lymphoid tissue—skin cancer	8.74e-05	0.00278	CbGeAlD
Sorafenib—PDGFRB—lymphoid tissue—skin cancer	8.54e-05	0.00271	CbGeAlD
Sorafenib—FLT4—lymph node—skin cancer	8.47e-05	0.00269	CbGeAlD
Sorafenib—KIT—female reproductive system—skin cancer	8.43e-05	0.00268	CbGeAlD
Sorafenib—FGFR1—lymph node—skin cancer	8.36e-05	0.00265	CbGeAlD
Sorafenib—HTR2B—skin of body—skin cancer	8.35e-05	0.00265	CbGeAlD
Sorafenib—PDGFRB—female reproductive system—skin cancer	8.24e-05	0.00261	CbGeAlD
Sorafenib—KDR—head—skin cancer	7.95e-05	0.00252	CbGeAlD
Sorafenib—MAP2K5—head—skin cancer	7.95e-05	0.00252	CbGeAlD
Sorafenib—MAP3K7—lymph node—skin cancer	7.91e-05	0.00251	CbGeAlD
Sorafenib—CSF1R—head—skin cancer	7.76e-05	0.00246	CbGeAlD
Sorafenib—MKNK2—lymph node—skin cancer	7.67e-05	0.00243	CbGeAlD
Sorafenib—MKNK1—lymph node—skin cancer	7.57e-05	0.0024	CbGeAlD
Sorafenib—RET—lymph node—skin cancer	7.48e-05	0.00237	CbGeAlD
Sorafenib—KIT—head—skin cancer	7.05e-05	0.00224	CbGeAlD
Sorafenib—HTR2C—female reproductive system—skin cancer	6.95e-05	0.0022	CbGeAlD
Sorafenib—RALBP1—lymph node—skin cancer	6.92e-05	0.0022	CbGeAlD
Sorafenib—PDGFRB—head—skin cancer	6.88e-05	0.00218	CbGeAlD
Sorafenib—FLT1—lymph node—skin cancer	6.59e-05	0.00209	CbGeAlD
Sorafenib—ABCC4—female reproductive system—skin cancer	6.56e-05	0.00208	CbGeAlD
Sorafenib—RAF1—lymph node—skin cancer	6.55e-05	0.00208	CbGeAlD
Sorafenib—HTR2B—female reproductive system—skin cancer	6.52e-05	0.00207	CbGeAlD
Sorafenib—EPHB6—lymph node—skin cancer	6.51e-05	0.00207	CbGeAlD
Sorafenib—ABCC2—female reproductive system—skin cancer	6.35e-05	0.00201	CbGeAlD
Sorafenib—ABCB1—blood vessel—skin cancer	6.31e-05	0.002	CbGeAlD
Sorafenib—Hepatobiliary disease—Temozolomide—skin cancer	6.25e-05	0.00113	CcSEcCtD
Sorafenib—STK10—lymph node—skin cancer	6.23e-05	0.00198	CbGeAlD
Sorafenib—Alopecia—Bleomycin—skin cancer	6.22e-05	0.00112	CcSEcCtD
Sorafenib—Erythema multiforme—Dactinomycin—skin cancer	6.2e-05	0.00112	CcSEcCtD
Sorafenib—Dyspepsia—Imiquimod—skin cancer	6.19e-05	0.00112	CcSEcCtD
Sorafenib—PDGFRA—lymph node—skin cancer	6.17e-05	0.00196	CbGeAlD
Sorafenib—Pneumonia—Fluorouracil—skin cancer	6.13e-05	0.00111	CcSEcCtD
Sorafenib—Erythema—Bleomycin—skin cancer	6.12e-05	0.00111	CcSEcCtD
Sorafenib—Decreased appetite—Imiquimod—skin cancer	6.11e-05	0.0011	CcSEcCtD
Sorafenib—Infestation NOS—Fluorouracil—skin cancer	6.09e-05	0.0011	CcSEcCtD
Sorafenib—Infestation—Fluorouracil—skin cancer	6.09e-05	0.0011	CcSEcCtD
Sorafenib—Flushing—Dactinomycin—skin cancer	6.09e-05	0.0011	CcSEcCtD
Sorafenib—Hypersensitivity—Vemurafenib—skin cancer	6.08e-05	0.0011	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Imiquimod—skin cancer	6.07e-05	0.0011	CcSEcCtD
Sorafenib—Fatigue—Imiquimod—skin cancer	6.06e-05	0.0011	CcSEcCtD
Sorafenib—Pain—Imiquimod—skin cancer	6.02e-05	0.00109	CcSEcCtD
Sorafenib—Acute coronary syndrome—Fluorouracil—skin cancer	6e-05	0.00108	CcSEcCtD
Sorafenib—Myocardial infarction—Fluorouracil—skin cancer	5.97e-05	0.00108	CcSEcCtD
Sorafenib—Neuropathy peripheral—Fluorouracil—skin cancer	5.97e-05	0.00108	CcSEcCtD
Sorafenib—Haemoglobin—Temozolomide—skin cancer	5.96e-05	0.00108	CcSEcCtD
Sorafenib—Stomatitis—Fluorouracil—skin cancer	5.94e-05	0.00107	CcSEcCtD
Sorafenib—Haemorrhage—Temozolomide—skin cancer	5.93e-05	0.00107	CcSEcCtD
Sorafenib—Asthenia—Vemurafenib—skin cancer	5.92e-05	0.00107	CcSEcCtD
Sorafenib—Urinary tract disorder—Temozolomide—skin cancer	5.86e-05	0.00106	CcSEcCtD
Sorafenib—Cardiac failure—Docetaxel—skin cancer	5.84e-05	0.00106	CcSEcCtD
Sorafenib—Pruritus—Vemurafenib—skin cancer	5.84e-05	0.00105	CcSEcCtD
Sorafenib—Connective tissue disorder—Temozolomide—skin cancer	5.83e-05	0.00105	CcSEcCtD
Sorafenib—Urethral disorder—Temozolomide—skin cancer	5.82e-05	0.00105	CcSEcCtD
Sorafenib—HTR2C—head—skin cancer	5.8e-05	0.00184	CbGeAlD
Sorafenib—Alopecia—Dactinomycin—skin cancer	5.8e-05	0.00105	CcSEcCtD
Sorafenib—Gastrointestinal pain—Imiquimod—skin cancer	5.75e-05	0.00104	CcSEcCtD
Sorafenib—Epistaxis—Fluorouracil—skin cancer	5.74e-05	0.00104	CcSEcCtD
Sorafenib—Hyponatraemia—Docetaxel—skin cancer	5.73e-05	0.00103	CcSEcCtD
Sorafenib—Erythema—Dactinomycin—skin cancer	5.71e-05	0.00103	CcSEcCtD
Sorafenib—Pain in extremity—Docetaxel—skin cancer	5.7e-05	0.00103	CcSEcCtD
Sorafenib—Anaemia—Bleomycin—skin cancer	5.66e-05	0.00102	CcSEcCtD
Sorafenib—Diarrhoea—Vemurafenib—skin cancer	5.64e-05	0.00102	CcSEcCtD
Sorafenib—Erythema multiforme—Temozolomide—skin cancer	5.61e-05	0.00101	CcSEcCtD
Sorafenib—Urticaria—Imiquimod—skin cancer	5.59e-05	0.00101	CcSEcCtD
Sorafenib—MAP2K5—lymph node—skin cancer	5.57e-05	0.00177	CbGeAlD
Sorafenib—KDR—lymph node—skin cancer	5.57e-05	0.00177	CbGeAlD
Sorafenib—Abdominal pain—Imiquimod—skin cancer	5.56e-05	0.001	CcSEcCtD
Sorafenib—Body temperature increased—Imiquimod—skin cancer	5.56e-05	0.001	CcSEcCtD
Sorafenib—Tinnitus—Temozolomide—skin cancer	5.53e-05	0.000999	CcSEcCtD
Sorafenib—Cardiac disorder—Temozolomide—skin cancer	5.51e-05	0.000995	CcSEcCtD
Sorafenib—Flushing—Temozolomide—skin cancer	5.51e-05	0.000995	CcSEcCtD
Sorafenib—Haemoglobin—Fluorouracil—skin cancer	5.49e-05	0.000992	CcSEcCtD
Sorafenib—Leukopenia—Bleomycin—skin cancer	5.48e-05	0.00099	CcSEcCtD
Sorafenib—ABCC4—head—skin cancer	5.48e-05	0.00174	CbGeAlD
Sorafenib—CYP2B6—skin of body—skin cancer	5.47e-05	0.00174	CbGeAlD
Sorafenib—Haemorrhage—Fluorouracil—skin cancer	5.47e-05	0.000987	CcSEcCtD
Sorafenib—Dizziness—Vemurafenib—skin cancer	5.45e-05	0.000985	CcSEcCtD
Sorafenib—HTR2B—head—skin cancer	5.45e-05	0.00173	CbGeAlD
Sorafenib—CSF1R—lymph node—skin cancer	5.43e-05	0.00172	CbGeAlD
Sorafenib—ABCG2—mammalian vulva—skin cancer	5.41e-05	0.00172	CbGeAlD
Sorafenib—Angiopathy—Temozolomide—skin cancer	5.38e-05	0.000972	CcSEcCtD
Sorafenib—Immune system disorder—Temozolomide—skin cancer	5.36e-05	0.000968	CcSEcCtD
Sorafenib—Mediastinal disorder—Temozolomide—skin cancer	5.35e-05	0.000966	CcSEcCtD
Sorafenib—Cough—Bleomycin—skin cancer	5.34e-05	0.000965	CcSEcCtD
Sorafenib—Dehydration—Docetaxel—skin cancer	5.3e-05	0.000958	CcSEcCtD
Sorafenib—Anaemia—Dactinomycin—skin cancer	5.28e-05	0.000953	CcSEcCtD
Sorafenib—Vomiting—Vemurafenib—skin cancer	5.24e-05	0.000947	CcSEcCtD
Sorafenib—Alopecia—Temozolomide—skin cancer	5.24e-05	0.000947	CcSEcCtD
Sorafenib—Dry skin—Docetaxel—skin cancer	5.23e-05	0.000944	CcSEcCtD
Sorafenib—Myalgia—Bleomycin—skin cancer	5.21e-05	0.000942	CcSEcCtD
Sorafenib—Abdominal pain upper—Docetaxel—skin cancer	5.21e-05	0.000941	CcSEcCtD
Sorafenib—Rash—Vemurafenib—skin cancer	5.2e-05	0.000939	CcSEcCtD
Sorafenib—Mental disorder—Temozolomide—skin cancer	5.2e-05	0.000939	CcSEcCtD
Sorafenib—Dermatitis—Vemurafenib—skin cancer	5.2e-05	0.000938	CcSEcCtD
Sorafenib—Hypersensitivity—Imiquimod—skin cancer	5.18e-05	0.000936	CcSEcCtD
Sorafenib—Headache—Vemurafenib—skin cancer	5.17e-05	0.000933	CcSEcCtD
Sorafenib—Erythema—Temozolomide—skin cancer	5.16e-05	0.000933	CcSEcCtD
Sorafenib—Malnutrition—Temozolomide—skin cancer	5.16e-05	0.000933	CcSEcCtD
Sorafenib—Breast disorder—Docetaxel—skin cancer	5.15e-05	0.000931	CcSEcCtD
Sorafenib—Aspartate aminotransferase increased—Docetaxel—skin cancer	5.14e-05	0.000928	CcSEcCtD
Sorafenib—Toxic epidermal necrolysis—Docetaxel—skin cancer	5.14e-05	0.000928	CcSEcCtD
Sorafenib—Leukopenia—Dactinomycin—skin cancer	5.11e-05	0.000923	CcSEcCtD
Sorafenib—Nasopharyngitis—Docetaxel—skin cancer	5.1e-05	0.000921	CcSEcCtD
Sorafenib—Dysgeusia—Temozolomide—skin cancer	5.06e-05	0.000914	CcSEcCtD
Sorafenib—Asthenia—Imiquimod—skin cancer	5.05e-05	0.000912	CcSEcCtD
Sorafenib—Alanine aminotransferase increased—Docetaxel—skin cancer	5.03e-05	0.000909	CcSEcCtD
Sorafenib—Anaphylactic shock—Bleomycin—skin cancer	5e-05	0.000903	CcSEcCtD
Sorafenib—Pruritus—Imiquimod—skin cancer	4.98e-05	0.000899	CcSEcCtD
Sorafenib—Infection—Bleomycin—skin cancer	4.96e-05	0.000897	CcSEcCtD
Sorafenib—KIT—lymph node—skin cancer	4.93e-05	0.00157	CbGeAlD
Sorafenib—Dysphagia—Docetaxel—skin cancer	4.93e-05	0.00089	CcSEcCtD
Sorafenib—Nausea—Vemurafenib—skin cancer	4.9e-05	0.000885	CcSEcCtD
Sorafenib—Thrombocytopenia—Bleomycin—skin cancer	4.89e-05	0.000884	CcSEcCtD
Sorafenib—Arrhythmia—Fluorouracil—skin cancer	4.88e-05	0.000882	CcSEcCtD
Sorafenib—Myalgia—Dactinomycin—skin cancer	4.86e-05	0.000878	CcSEcCtD
Sorafenib—Alopecia—Fluorouracil—skin cancer	4.83e-05	0.000873	CcSEcCtD
Sorafenib—PDGFRB—lymph node—skin cancer	4.82e-05	0.00153	CbGeAlD
Sorafenib—Diarrhoea—Imiquimod—skin cancer	4.81e-05	0.000869	CcSEcCtD
Sorafenib—Anaemia—Temozolomide—skin cancer	4.77e-05	0.000862	CcSEcCtD
Sorafenib—Anorexia—Bleomycin—skin cancer	4.76e-05	0.00086	CcSEcCtD
Sorafenib—CYP2C8—female reproductive system—skin cancer	4.76e-05	0.00151	CbGeAlD
Sorafenib—Erythema—Fluorouracil—skin cancer	4.76e-05	0.00086	CcSEcCtD
Sorafenib—Angioedema—Temozolomide—skin cancer	4.72e-05	0.000852	CcSEcCtD
Sorafenib—Dizziness—Imiquimod—skin cancer	4.65e-05	0.00084	CcSEcCtD
Sorafenib—Infection—Dactinomycin—skin cancer	4.63e-05	0.000836	CcSEcCtD
Sorafenib—Leukopenia—Temozolomide—skin cancer	4.62e-05	0.000835	CcSEcCtD
Sorafenib—Neutropenia—Docetaxel—skin cancer	4.61e-05	0.000833	CcSEcCtD
Sorafenib—Thrombocytopenia—Dactinomycin—skin cancer	4.56e-05	0.000824	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Bleomycin—skin cancer	4.55e-05	0.000822	CcSEcCtD
Sorafenib—Cough—Temozolomide—skin cancer	4.51e-05	0.000814	CcSEcCtD
Sorafenib—Vomiting—Imiquimod—skin cancer	4.47e-05	0.000808	CcSEcCtD
Sorafenib—Weight decreased—Docetaxel—skin cancer	4.46e-05	0.000806	CcSEcCtD
Sorafenib—Hypertension—Temozolomide—skin cancer	4.46e-05	0.000805	CcSEcCtD
Sorafenib—Dyspnoea—Bleomycin—skin cancer	4.46e-05	0.000805	CcSEcCtD
Sorafenib—Anorexia—Dactinomycin—skin cancer	4.44e-05	0.000802	CcSEcCtD
Sorafenib—Rash—Imiquimod—skin cancer	4.44e-05	0.000801	CcSEcCtD
Sorafenib—Dermatitis—Imiquimod—skin cancer	4.43e-05	0.0008	CcSEcCtD
Sorafenib—CYP2B6—lymphoid tissue—skin cancer	4.43e-05	0.00141	CbGeAlD
Sorafenib—Pneumonia—Docetaxel—skin cancer	4.42e-05	0.000799	CcSEcCtD
Sorafenib—Headache—Imiquimod—skin cancer	4.41e-05	0.000796	CcSEcCtD
Sorafenib—Anaemia—Fluorouracil—skin cancer	4.4e-05	0.000794	CcSEcCtD
Sorafenib—Myalgia—Temozolomide—skin cancer	4.4e-05	0.000794	CcSEcCtD
Sorafenib—Arthralgia—Temozolomide—skin cancer	4.4e-05	0.000794	CcSEcCtD
Sorafenib—Infestation NOS—Docetaxel—skin cancer	4.4e-05	0.000794	CcSEcCtD
Sorafenib—Infestation—Docetaxel—skin cancer	4.4e-05	0.000794	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	4.37e-05	0.000789	CcSEcCtD
Sorafenib—Stevens-Johnson syndrome—Docetaxel—skin cancer	4.36e-05	0.000787	CcSEcCtD
Sorafenib—Decreased appetite—Bleomycin—skin cancer	4.34e-05	0.000785	CcSEcCtD
Sorafenib—Acute coronary syndrome—Docetaxel—skin cancer	4.33e-05	0.000783	CcSEcCtD
Sorafenib—Renal failure—Docetaxel—skin cancer	4.32e-05	0.00078	CcSEcCtD
Sorafenib—Myocardial infarction—Docetaxel—skin cancer	4.31e-05	0.000778	CcSEcCtD
Sorafenib—Neuropathy peripheral—Docetaxel—skin cancer	4.31e-05	0.000778	CcSEcCtD
Sorafenib—Dry mouth—Temozolomide—skin cancer	4.3e-05	0.000777	CcSEcCtD
Sorafenib—Jaundice—Docetaxel—skin cancer	4.28e-05	0.000774	CcSEcCtD
Sorafenib—Stomatitis—Docetaxel—skin cancer	4.28e-05	0.000774	CcSEcCtD
Sorafenib—Pain—Bleomycin—skin cancer	4.27e-05	0.000772	CcSEcCtD
Sorafenib—CYP2B6—female reproductive system—skin cancer	4.27e-05	0.00136	CbGeAlD
Sorafenib—Leukopenia—Fluorouracil—skin cancer	4.26e-05	0.000769	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Dactinomycin—skin cancer	4.25e-05	0.000767	CcSEcCtD
Sorafenib—CYP2C9—female reproductive system—skin cancer	4.23e-05	0.00134	CbGeAlD
Sorafenib—Anaphylactic shock—Temozolomide—skin cancer	4.22e-05	0.000761	CcSEcCtD
Sorafenib—Infection—Temozolomide—skin cancer	4.19e-05	0.000756	CcSEcCtD
Sorafenib—Nausea—Imiquimod—skin cancer	4.18e-05	0.000755	CcSEcCtD
Sorafenib—Hepatobiliary disease—Docetaxel—skin cancer	4.16e-05	0.000751	CcSEcCtD
Sorafenib—Epistaxis—Docetaxel—skin cancer	4.15e-05	0.000749	CcSEcCtD
Sorafenib—Nervous system disorder—Temozolomide—skin cancer	4.13e-05	0.000747	CcSEcCtD
Sorafenib—Thrombocytopenia—Temozolomide—skin cancer	4.13e-05	0.000745	CcSEcCtD
Sorafenib—Skin disorder—Temozolomide—skin cancer	4.09e-05	0.00074	CcSEcCtD
Sorafenib—Myalgia—Fluorouracil—skin cancer	4.05e-05	0.000732	CcSEcCtD
Sorafenib—Decreased appetite—Dactinomycin—skin cancer	4.05e-05	0.000732	CcSEcCtD
Sorafenib—Fatigue—Dactinomycin—skin cancer	4.02e-05	0.000726	CcSEcCtD
Sorafenib—Anorexia—Temozolomide—skin cancer	4.02e-05	0.000726	CcSEcCtD
Sorafenib—Pain—Dactinomycin—skin cancer	3.99e-05	0.00072	CcSEcCtD
Sorafenib—Urticaria—Bleomycin—skin cancer	3.97e-05	0.000717	CcSEcCtD
Sorafenib—Haemoglobin—Docetaxel—skin cancer	3.97e-05	0.000716	CcSEcCtD
Sorafenib—Body temperature increased—Bleomycin—skin cancer	3.95e-05	0.000714	CcSEcCtD
Sorafenib—Haemorrhage—Docetaxel—skin cancer	3.95e-05	0.000713	CcSEcCtD
Sorafenib—Urinary tract disorder—Docetaxel—skin cancer	3.9e-05	0.000704	CcSEcCtD
Sorafenib—Anaphylactic shock—Fluorouracil—skin cancer	3.88e-05	0.000702	CcSEcCtD
Sorafenib—Connective tissue disorder—Docetaxel—skin cancer	3.88e-05	0.0007	CcSEcCtD
Sorafenib—Urethral disorder—Docetaxel—skin cancer	3.87e-05	0.000699	CcSEcCtD
Sorafenib—Infection—Fluorouracil—skin cancer	3.86e-05	0.000697	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Temozolomide—skin cancer	3.84e-05	0.000694	CcSEcCtD
Sorafenib—ABCC4—lymph node—skin cancer	3.84e-05	0.00122	CbGeAlD
Sorafenib—HTR2B—lymph node—skin cancer	3.82e-05	0.00121	CbGeAlD
Sorafenib—Gastrointestinal pain—Dactinomycin—skin cancer	3.81e-05	0.000688	CcSEcCtD
Sorafenib—Nervous system disorder—Fluorouracil—skin cancer	3.81e-05	0.000688	CcSEcCtD
Sorafenib—Thrombocytopenia—Fluorouracil—skin cancer	3.8e-05	0.000687	CcSEcCtD
Sorafenib—Dyspnoea—Temozolomide—skin cancer	3.76e-05	0.000679	CcSEcCtD
Sorafenib—Erythema multiforme—Docetaxel—skin cancer	3.73e-05	0.000674	CcSEcCtD
Sorafenib—ABCC2—lymph node—skin cancer	3.71e-05	0.00118	CbGeAlD
Sorafenib—Dyspepsia—Temozolomide—skin cancer	3.71e-05	0.00067	CcSEcCtD
Sorafenib—Anorexia—Fluorouracil—skin cancer	3.7e-05	0.000669	CcSEcCtD
Sorafenib—Body temperature increased—Dactinomycin—skin cancer	3.68e-05	0.000665	CcSEcCtD
Sorafenib—Abdominal pain—Dactinomycin—skin cancer	3.68e-05	0.000665	CcSEcCtD
Sorafenib—Hypersensitivity—Bleomycin—skin cancer	3.68e-05	0.000665	CcSEcCtD
Sorafenib—Decreased appetite—Temozolomide—skin cancer	3.66e-05	0.000662	CcSEcCtD
Sorafenib—Flushing—Docetaxel—skin cancer	3.66e-05	0.000661	CcSEcCtD
Sorafenib—Cardiac disorder—Docetaxel—skin cancer	3.66e-05	0.000661	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Temozolomide—skin cancer	3.64e-05	0.000657	CcSEcCtD
Sorafenib—Fatigue—Temozolomide—skin cancer	3.63e-05	0.000656	CcSEcCtD
Sorafenib—Constipation—Temozolomide—skin cancer	3.6e-05	0.000651	CcSEcCtD
Sorafenib—Pain—Temozolomide—skin cancer	3.6e-05	0.000651	CcSEcCtD
Sorafenib—Asthenia—Bleomycin—skin cancer	3.59e-05	0.000648	CcSEcCtD
Sorafenib—Angiopathy—Docetaxel—skin cancer	3.58e-05	0.000647	CcSEcCtD
Sorafenib—CYP2B6—head—skin cancer	3.57e-05	0.00113	CbGeAlD
Sorafenib—Immune system disorder—Docetaxel—skin cancer	3.56e-05	0.000644	CcSEcCtD
Sorafenib—Mediastinal disorder—Docetaxel—skin cancer	3.56e-05	0.000642	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Fluorouracil—skin cancer	3.54e-05	0.000639	CcSEcCtD
Sorafenib—Pruritus—Bleomycin—skin cancer	3.54e-05	0.000639	CcSEcCtD
Sorafenib—Arrhythmia—Docetaxel—skin cancer	3.52e-05	0.000637	CcSEcCtD
Sorafenib—Alopecia—Docetaxel—skin cancer	3.49e-05	0.00063	CcSEcCtD
Sorafenib—Dyspnoea—Fluorouracil—skin cancer	3.46e-05	0.000625	CcSEcCtD
Sorafenib—Mental disorder—Docetaxel—skin cancer	3.46e-05	0.000624	CcSEcCtD
Sorafenib—Gastrointestinal pain—Temozolomide—skin cancer	3.45e-05	0.000623	CcSEcCtD
Sorafenib—Malnutrition—Docetaxel—skin cancer	3.43e-05	0.00062	CcSEcCtD
Sorafenib—Erythema—Docetaxel—skin cancer	3.43e-05	0.00062	CcSEcCtD
Sorafenib—Hypersensitivity—Dactinomycin—skin cancer	3.43e-05	0.00062	CcSEcCtD
Sorafenib—Dyspepsia—Fluorouracil—skin cancer	3.42e-05	0.000618	CcSEcCtD
Sorafenib—Decreased appetite—Fluorouracil—skin cancer	3.38e-05	0.00061	CcSEcCtD
Sorafenib—Dysgeusia—Docetaxel—skin cancer	3.36e-05	0.000608	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Fluorouracil—skin cancer	3.35e-05	0.000606	CcSEcCtD
Sorafenib—Urticaria—Temozolomide—skin cancer	3.35e-05	0.000605	CcSEcCtD
Sorafenib—Asthenia—Dactinomycin—skin cancer	3.34e-05	0.000604	CcSEcCtD
Sorafenib—Abdominal pain—Temozolomide—skin cancer	3.33e-05	0.000602	CcSEcCtD
Sorafenib—Body temperature increased—Temozolomide—skin cancer	3.33e-05	0.000602	CcSEcCtD
Sorafenib—Pain—Fluorouracil—skin cancer	3.32e-05	0.0006	CcSEcCtD
Sorafenib—Muscle spasms—Docetaxel—skin cancer	3.3e-05	0.000596	CcSEcCtD
Sorafenib—CYP3A4—female reproductive system—skin cancer	3.23e-05	0.00102	CbGeAlD
Sorafenib—Diarrhoea—Dactinomycin—skin cancer	3.19e-05	0.000576	CcSEcCtD
Sorafenib—Vomiting—Bleomycin—skin cancer	3.18e-05	0.000574	CcSEcCtD
Sorafenib—Anaemia—Docetaxel—skin cancer	3.17e-05	0.000573	CcSEcCtD
Sorafenib—CYP2D6—female reproductive system—skin cancer	3.17e-05	0.00101	CbGeAlD
Sorafenib—Rash—Bleomycin—skin cancer	3.15e-05	0.000569	CcSEcCtD
Sorafenib—Dermatitis—Bleomycin—skin cancer	3.15e-05	0.000569	CcSEcCtD
Sorafenib—Hypersensitivity—Temozolomide—skin cancer	3.11e-05	0.000561	CcSEcCtD
Sorafenib—Urticaria—Fluorouracil—skin cancer	3.09e-05	0.000557	CcSEcCtD
Sorafenib—Syncope—Docetaxel—skin cancer	3.08e-05	0.000556	CcSEcCtD
Sorafenib—Leukopenia—Docetaxel—skin cancer	3.07e-05	0.000555	CcSEcCtD
Sorafenib—ABCB1—epithelium—skin cancer	3.07e-05	0.000975	CbGeAlD
Sorafenib—Body temperature increased—Fluorouracil—skin cancer	3.07e-05	0.000555	CcSEcCtD
Sorafenib—Asthenia—Temozolomide—skin cancer	3.02e-05	0.000546	CcSEcCtD
Sorafenib—Loss of consciousness—Docetaxel—skin cancer	3.02e-05	0.000545	CcSEcCtD
Sorafenib—Cough—Docetaxel—skin cancer	3e-05	0.000541	CcSEcCtD
Sorafenib—Pruritus—Temozolomide—skin cancer	2.98e-05	0.000539	CcSEcCtD
Sorafenib—Nausea—Bleomycin—skin cancer	2.97e-05	0.000536	CcSEcCtD
Sorafenib—Hypertension—Docetaxel—skin cancer	2.97e-05	0.000536	CcSEcCtD
Sorafenib—Vomiting—Dactinomycin—skin cancer	2.96e-05	0.000535	CcSEcCtD
Sorafenib—Rash—Dactinomycin—skin cancer	2.94e-05	0.000531	CcSEcCtD
Sorafenib—Myalgia—Docetaxel—skin cancer	2.92e-05	0.000528	CcSEcCtD
Sorafenib—Arthralgia—Docetaxel—skin cancer	2.92e-05	0.000528	CcSEcCtD
Sorafenib—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	2.9e-05	0.000525	CcSEcCtD
Sorafenib—Diarrhoea—Temozolomide—skin cancer	2.88e-05	0.000521	CcSEcCtD
Sorafenib—Hypersensitivity—Fluorouracil—skin cancer	2.86e-05	0.000517	CcSEcCtD
Sorafenib—Dry mouth—Docetaxel—skin cancer	2.86e-05	0.000517	CcSEcCtD
Sorafenib—Anaphylactic shock—Docetaxel—skin cancer	2.8e-05	0.000506	CcSEcCtD
Sorafenib—Dizziness—Temozolomide—skin cancer	2.79e-05	0.000503	CcSEcCtD
Sorafenib—Infection—Docetaxel—skin cancer	2.78e-05	0.000503	CcSEcCtD
Sorafenib—Nausea—Dactinomycin—skin cancer	2.77e-05	0.0005	CcSEcCtD
Sorafenib—Shock—Docetaxel—skin cancer	2.76e-05	0.000498	CcSEcCtD
Sorafenib—Nervous system disorder—Docetaxel—skin cancer	2.75e-05	0.000497	CcSEcCtD
Sorafenib—Pruritus—Fluorouracil—skin cancer	2.75e-05	0.000496	CcSEcCtD
Sorafenib—Thrombocytopenia—Docetaxel—skin cancer	2.74e-05	0.000496	CcSEcCtD
Sorafenib—Skin disorder—Docetaxel—skin cancer	2.72e-05	0.000492	CcSEcCtD
Sorafenib—ABCG2—lymph node—skin cancer	2.71e-05	0.00086	CbGeAlD
Sorafenib—Vomiting—Temozolomide—skin cancer	2.68e-05	0.000484	CcSEcCtD
Sorafenib—Anorexia—Docetaxel—skin cancer	2.67e-05	0.000483	CcSEcCtD
Sorafenib—ABCB1—mammalian vulva—skin cancer	2.67e-05	0.000846	CbGeAlD
Sorafenib—Rash—Temozolomide—skin cancer	2.66e-05	0.00048	CcSEcCtD
Sorafenib—Diarrhoea—Fluorouracil—skin cancer	2.66e-05	0.00048	CcSEcCtD
Sorafenib—Dermatitis—Temozolomide—skin cancer	2.66e-05	0.00048	CcSEcCtD
Sorafenib—CYP2D6—head—skin cancer	2.65e-05	0.000842	CbGeAlD
Sorafenib—Headache—Temozolomide—skin cancer	2.64e-05	0.000477	CcSEcCtD
Sorafenib—Dizziness—Fluorouracil—skin cancer	2.57e-05	0.000464	CcSEcCtD
Sorafenib—Musculoskeletal discomfort—Docetaxel—skin cancer	2.55e-05	0.000461	CcSEcCtD
Sorafenib—Nausea—Temozolomide—skin cancer	2.5e-05	0.000452	CcSEcCtD
Sorafenib—Dyspnoea—Docetaxel—skin cancer	2.5e-05	0.000451	CcSEcCtD
Sorafenib—Vomiting—Fluorouracil—skin cancer	2.47e-05	0.000446	CcSEcCtD
Sorafenib—Dyspepsia—Docetaxel—skin cancer	2.47e-05	0.000446	CcSEcCtD
Sorafenib—Rash—Fluorouracil—skin cancer	2.45e-05	0.000442	CcSEcCtD
Sorafenib—Dermatitis—Fluorouracil—skin cancer	2.45e-05	0.000442	CcSEcCtD
Sorafenib—Decreased appetite—Docetaxel—skin cancer	2.44e-05	0.00044	CcSEcCtD
Sorafenib—Headache—Fluorouracil—skin cancer	2.43e-05	0.000439	CcSEcCtD
Sorafenib—Gastrointestinal disorder—Docetaxel—skin cancer	2.42e-05	0.000437	CcSEcCtD
Sorafenib—Fatigue—Docetaxel—skin cancer	2.42e-05	0.000437	CcSEcCtD
Sorafenib—Constipation—Docetaxel—skin cancer	2.4e-05	0.000433	CcSEcCtD
Sorafenib—Pain—Docetaxel—skin cancer	2.4e-05	0.000433	CcSEcCtD
Sorafenib—ABCB1—lymphoid tissue—skin cancer	2.37e-05	0.000751	CbGeAlD
Sorafenib—Nausea—Fluorouracil—skin cancer	2.31e-05	0.000417	CcSEcCtD
Sorafenib—Gastrointestinal pain—Docetaxel—skin cancer	2.29e-05	0.000414	CcSEcCtD
Sorafenib—ABCB1—female reproductive system—skin cancer	2.28e-05	0.000725	CbGeAlD
Sorafenib—Body temperature increased—Docetaxel—skin cancer	2.22e-05	0.0004	CcSEcCtD
Sorafenib—Abdominal pain—Docetaxel—skin cancer	2.22e-05	0.0004	CcSEcCtD
Sorafenib—Hypersensitivity—Docetaxel—skin cancer	2.07e-05	0.000373	CcSEcCtD
Sorafenib—Asthenia—Docetaxel—skin cancer	2.01e-05	0.000363	CcSEcCtD
Sorafenib—Pruritus—Docetaxel—skin cancer	1.98e-05	0.000358	CcSEcCtD
Sorafenib—Diarrhoea—Docetaxel—skin cancer	1.92e-05	0.000346	CcSEcCtD
Sorafenib—ABCB1—head—skin cancer	1.91e-05	0.000605	CbGeAlD
Sorafenib—Dizziness—Docetaxel—skin cancer	1.85e-05	0.000335	CcSEcCtD
Sorafenib—Vomiting—Docetaxel—skin cancer	1.78e-05	0.000322	CcSEcCtD
Sorafenib—Rash—Docetaxel—skin cancer	1.77e-05	0.000319	CcSEcCtD
Sorafenib—Dermatitis—Docetaxel—skin cancer	1.77e-05	0.000319	CcSEcCtD
Sorafenib—Headache—Docetaxel—skin cancer	1.76e-05	0.000317	CcSEcCtD
Sorafenib—Nausea—Docetaxel—skin cancer	1.67e-05	0.000301	CcSEcCtD
Sorafenib—ABCB1—lymph node—skin cancer	1.34e-05	0.000424	CbGeAlD
Sorafenib—MAP2K5—Signaling Pathways—BRAF—skin cancer	2.42e-06	5.85e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ENO2—skin cancer	2.41e-06	5.82e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—HRAS—skin cancer	2.4e-06	5.8e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—KRAS—skin cancer	2.39e-06	5.79e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—KRAS—skin cancer	2.39e-06	5.77e-05	CbGpPWpGaD
Sorafenib—MAPK11—Innate Immune System—IL6—skin cancer	2.37e-06	5.73e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—BRAF—skin cancer	2.36e-06	5.7e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—TP53—skin cancer	2.34e-06	5.67e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—TP53—skin cancer	2.32e-06	5.61e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—NRAS—skin cancer	2.32e-06	5.61e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—PTGS2—skin cancer	2.32e-06	5.6e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TERT—skin cancer	2.31e-06	5.58e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TERT—skin cancer	2.31e-06	5.58e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—ERCC2—skin cancer	2.3e-06	5.57e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—ERCC2—skin cancer	2.3e-06	5.57e-05	CbGpPWpGaD
Sorafenib—FGFR1—Developmental Biology—IL6—skin cancer	2.3e-06	5.55e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—TP53—skin cancer	2.28e-06	5.52e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	2.28e-06	5.51e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—FOXO4—skin cancer	2.27e-06	5.48e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—KRAS—skin cancer	2.26e-06	5.47e-05	CbGpPWpGaD
Sorafenib—ABCC4—Hemostasis—HRAS—skin cancer	2.24e-06	5.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—KRAS—skin cancer	2.24e-06	5.42e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—HRAS—skin cancer	2.23e-06	5.4e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—HRAS—skin cancer	2.23e-06	5.4e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—NRAS—skin cancer	2.23e-06	5.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—NRAS—skin cancer	2.23e-06	5.39e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—BRAF—skin cancer	2.23e-06	5.38e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—HRAS—skin cancer	2.22e-06	5.37e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—KRAS—skin cancer	2.22e-06	5.36e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TERT—skin cancer	2.19e-06	5.3e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TERT—skin cancer	2.19e-06	5.28e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—HRAS—skin cancer	2.18e-06	5.28e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—KRAS—skin cancer	2.15e-06	5.2e-05	CbGpPWpGaD
Sorafenib—KIT—Adaptive Immune System—HRAS—skin cancer	2.14e-06	5.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Adaptive Immune System—HRAS—skin cancer	2.14e-06	5.18e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—KRAS—skin cancer	2.14e-06	5.18e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Innate Immune System—IL6—skin cancer	2.14e-06	5.17e-05	CbGpPWpGaD
Sorafenib—KIT—Innate Immune System—IL6—skin cancer	2.14e-06	5.17e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—CSPG4—skin cancer	2.14e-06	5.16e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—KRAS—skin cancer	2.13e-06	5.15e-05	CbGpPWpGaD
Sorafenib—RALBP1—Signaling Pathways—IL6—skin cancer	2.13e-06	5.14e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—HRAS—skin cancer	2.12e-06	5.12e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—HRAS—skin cancer	2.11e-06	5.11e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—PTGS2—skin cancer	2.11e-06	5.1e-05	CbGpPWpGaD
Sorafenib—FLT4—Signaling Pathways—IL6—skin cancer	2.09e-06	5.05e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ENO2—skin cancer	2.09e-06	5.04e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PLIN2—skin cancer	2.04e-06	4.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Adaptive Immune System—HRAS—skin cancer	2.03e-06	4.92e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Adaptive Immune System—HRAS—skin cancer	2.03e-06	4.91e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—BRAF—skin cancer	2.03e-06	4.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Innate Immune System—IL6—skin cancer	2.03e-06	4.9e-05	CbGpPWpGaD
Sorafenib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	2.03e-06	4.9e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Innate Immune System—IL6—skin cancer	2.02e-06	4.89e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—PTGS2—skin cancer	2e-06	4.84e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—PTGS2—skin cancer	2e-06	4.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—KRAS—skin cancer	2e-06	4.83e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—BRAF—skin cancer	1.98e-06	4.8e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—NRAS—skin cancer	1.97e-06	4.77e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—TP53—skin cancer	1.97e-06	4.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TERT—skin cancer	1.97e-06	4.76e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—ERCC2—skin cancer	1.95e-06	4.72e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—ERCC2—skin cancer	1.94e-06	4.68e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—HRAS—skin cancer	1.92e-06	4.65e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—KRAS—skin cancer	1.92e-06	4.64e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—KRAS—skin cancer	1.92e-06	4.64e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—HRAS—skin cancer	1.9e-06	4.6e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—TP53—skin cancer	1.89e-06	4.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Hemostasis—HRAS—skin cancer	1.89e-06	4.56e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TERT—skin cancer	1.88e-06	4.54e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ENO2—skin cancer	1.86e-06	4.5e-05	CbGpPWpGaD
Sorafenib—RAF1—Developmental Biology—IL6—skin cancer	1.84e-06	4.45e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—BRAF—skin cancer	1.83e-06	4.42e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—BRAF—skin cancer	1.83e-06	4.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Adaptive Immune System—HRAS—skin cancer	1.83e-06	4.42e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Innate Immune System—IL6—skin cancer	1.82e-06	4.41e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—HRAS—skin cancer	1.82e-06	4.4e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ENO2—skin cancer	1.82e-06	4.4e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—HRAS—skin cancer	1.81e-06	4.38e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—NRAS—skin cancer	1.8e-06	4.36e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—PTGS2—skin cancer	1.8e-06	4.35e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—NRAS—skin cancer	1.78e-06	4.3e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—NRAS—skin cancer	1.78e-06	4.3e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TERT—skin cancer	1.76e-06	4.24e-05	CbGpPWpGaD
Sorafenib—CDK7—Disease—IL6—skin cancer	1.74e-06	4.21e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—BRAF—skin cancer	1.74e-06	4.2e-05	CbGpPWpGaD
Sorafenib—MKNK1—Signaling Pathways—IL6—skin cancer	1.73e-06	4.19e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—BRAF—skin cancer	1.73e-06	4.18e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ENO2—skin cancer	1.71e-06	4.14e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—TP53—skin cancer	1.7e-06	4.12e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ENO2—skin cancer	1.7e-06	4.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—HRAS—skin cancer	1.7e-06	4.1e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—KRAS—skin cancer	1.7e-06	4.1e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—NRAS—skin cancer	1.69e-06	4.08e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—NRAS—skin cancer	1.68e-06	4.07e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—CSPG4—skin cancer	1.65e-06	3.98e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—NRAS—skin cancer	1.64e-06	3.97e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.63e-06	3.95e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—HRAS—skin cancer	1.63e-06	3.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Adaptive Immune System—HRAS—skin cancer	1.63e-06	3.94e-05	CbGpPWpGaD
Sorafenib—RAF1—Innate Immune System—IL6—skin cancer	1.62e-06	3.93e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—PTGS2—skin cancer	1.6e-06	3.88e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—NRAS—skin cancer	1.58e-06	3.83e-05	CbGpPWpGaD
Sorafenib—FLT1—Signaling Pathways—IL6—skin cancer	1.56e-06	3.77e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—BRAF—skin cancer	1.56e-06	3.77e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—NRAS—skin cancer	1.56e-06	3.77e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—NRAS—skin cancer	1.55e-06	3.76e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—KRAS—skin cancer	1.55e-06	3.75e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—KRAS—skin cancer	1.53e-06	3.7e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—KRAS—skin cancer	1.53e-06	3.7e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—NRAS—skin cancer	1.52e-06	3.68e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—NRAS—skin cancer	1.52e-06	3.66e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TERT—skin cancer	1.52e-06	3.66e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—BRAF—skin cancer	1.49e-06	3.6e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—NRAS—skin cancer	1.48e-06	3.58e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—NRAS—skin cancer	1.48e-06	3.58e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.46e-06	3.52e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—KRAS—skin cancer	1.45e-06	3.51e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ENO2—skin cancer	1.45e-06	3.51e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—KRAS—skin cancer	1.45e-06	3.5e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—HRAS—skin cancer	1.44e-06	3.49e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—ERCC2—skin cancer	1.43e-06	3.46e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—KRAS—skin cancer	1.41e-06	3.41e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—NRAS—skin cancer	1.4e-06	3.38e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—ERCC2—skin cancer	1.4e-06	3.38e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—BRAF—skin cancer	1.39e-06	3.36e-05	CbGpPWpGaD
Sorafenib—MAPK11—Immune System—IL6—skin cancer	1.38e-06	3.34e-05	CbGpPWpGaD
Sorafenib—UGT1A1—Metabolism—PTGS2—skin cancer	1.38e-06	3.34e-05	CbGpPWpGaD
Sorafenib—UGT1A9—Metabolism—PTGS2—skin cancer	1.38e-06	3.34e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—KRAS—skin cancer	1.36e-06	3.29e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—NRAS—skin cancer	1.35e-06	3.27e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—KRAS—skin cancer	1.34e-06	3.24e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—KRAS—skin cancer	1.34e-06	3.23e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.33e-06	3.21e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—HRAS—skin cancer	1.32e-06	3.19e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—KRAS—skin cancer	1.31e-06	3.16e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—KRAS—skin cancer	1.3e-06	3.15e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—HRAS—skin cancer	1.3e-06	3.14e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—HRAS—skin cancer	1.3e-06	3.14e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—NRAS—skin cancer	1.28e-06	3.09e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—KRAS—skin cancer	1.28e-06	3.08e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—NRAS—skin cancer	1.27e-06	3.08e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—KRAS—skin cancer	1.27e-06	3.08e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—NRAS—skin cancer	1.26e-06	3.05e-05	CbGpPWpGaD
Sorafenib—BRAF—Disease—IL6—skin cancer	1.26e-06	3.05e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—NRAS—skin cancer	1.25e-06	3.02e-05	CbGpPWpGaD
Sorafenib—KIT—Immune System—IL6—skin cancer	1.24e-06	3.01e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Immune System—IL6—skin cancer	1.24e-06	3.01e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—HRAS—skin cancer	1.23e-06	2.98e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—HRAS—skin cancer	1.23e-06	2.98e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—ERCC2—skin cancer	1.21e-06	2.93e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—KRAS—skin cancer	1.2e-06	2.91e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—HRAS—skin cancer	1.2e-06	2.9e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—BRAF—skin cancer	1.2e-06	2.9e-05	CbGpPWpGaD
Sorafenib—FGFR1—Immune System—IL6—skin cancer	1.18e-06	2.86e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Immune System—IL6—skin cancer	1.18e-06	2.85e-05	CbGpPWpGaD
Sorafenib—ABCG2—Metabolism—PTGS2—skin cancer	1.17e-06	2.83e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—TP53—skin cancer	1.16e-06	2.81e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—KRAS—skin cancer	1.16e-06	2.81e-05	CbGpPWpGaD
Sorafenib—CYP3A7—Metabolism—PTGS2—skin cancer	1.16e-06	2.81e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—HRAS—skin cancer	1.16e-06	2.8e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—NRAS—skin cancer	1.15e-06	2.78e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—NRAS—skin cancer	1.15e-06	2.78e-05	CbGpPWpGaD
Sorafenib—KIT—Disease—IL6—skin cancer	1.15e-06	2.78e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—HRAS—skin cancer	1.14e-06	2.75e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—HRAS—skin cancer	1.14e-06	2.75e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.14e-06	2.74e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—TP53—skin cancer	1.13e-06	2.74e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ENO2—skin cancer	1.12e-06	2.71e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—HRAS—skin cancer	1.11e-06	2.69e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—HRAS—skin cancer	1.11e-06	2.68e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling by GPCR—IL6—skin cancer	1.11e-06	2.68e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—KRAS—skin cancer	1.1e-06	2.66e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—KRAS—skin cancer	1.1e-06	2.65e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—NRAS—skin cancer	1.09e-06	2.64e-05	CbGpPWpGaD
Sorafenib—FGFR1—Disease—IL6—skin cancer	1.09e-06	2.64e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—NRAS—skin cancer	1.09e-06	2.63e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Disease—IL6—skin cancer	1.09e-06	2.63e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—KRAS—skin cancer	1.09e-06	2.63e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—HRAS—skin cancer	1.08e-06	2.62e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—ERCC2—skin cancer	1.08e-06	2.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—HRAS—skin cancer	1.08e-06	2.62e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—KRAS—skin cancer	1.07e-06	2.6e-05	CbGpPWpGaD
Sorafenib—MAP2K5—Signaling Pathways—IL6—skin cancer	1.06e-06	2.57e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Immune System—IL6—skin cancer	1.06e-06	2.57e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—ERCC2—skin cancer	1.06e-06	2.55e-05	CbGpPWpGaD
Sorafenib—KDR—Signaling Pathways—IL6—skin cancer	1.04e-06	2.51e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling by GPCR—IL6—skin cancer	1.04e-06	2.5e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—HRAS—skin cancer	1.02e-06	2.48e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—ERCC2—skin cancer	9.95e-07	2.41e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—KRAS—skin cancer	9.89e-07	2.39e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—KRAS—skin cancer	9.89e-07	2.39e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—HRAS—skin cancer	9.88e-07	2.39e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—ERCC2—skin cancer	9.86e-07	2.38e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—NRAS—skin cancer	9.8e-07	2.37e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Disease—IL6—skin cancer	9.8e-07	2.37e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—TP53—skin cancer	9.75e-07	2.36e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—TP53—skin cancer	9.66e-07	2.34e-05	CbGpPWpGaD
Sorafenib—RAF1—Immune System—IL6—skin cancer	9.46e-07	2.29e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—KRAS—skin cancer	9.39e-07	2.27e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—KRAS—skin cancer	9.36e-07	2.26e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—NRAS—skin cancer	9.35e-07	2.26e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—HRAS—skin cancer	9.34e-07	2.26e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—HRAS—skin cancer	9.32e-07	2.25e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—HRAS—skin cancer	9.24e-07	2.23e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—HRAS—skin cancer	9.13e-07	2.21e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling by GPCR—IL6—skin cancer	8.94e-07	2.16e-05	CbGpPWpGaD
Sorafenib—MAPK11—Signaling Pathways—IL6—skin cancer	8.92e-07	2.16e-05	CbGpPWpGaD
Sorafenib—BRAF—Signaling Pathways—IL6—skin cancer	8.84e-07	2.14e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—TP53—skin cancer	8.79e-07	2.13e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—TP53—skin cancer	8.79e-07	2.13e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—NRAS—skin cancer	8.74e-07	2.11e-05	CbGpPWpGaD
Sorafenib—RAF1—Disease—IL6—skin cancer	8.73e-07	2.11e-05	CbGpPWpGaD
Sorafenib—CYP2B6—Metabolism—PTGS2—skin cancer	8.58e-07	2.08e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—KRAS—skin cancer	8.44e-07	2.04e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—ERCC2—skin cancer	8.43e-07	2.04e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—HRAS—skin cancer	8.41e-07	2.03e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—HRAS—skin cancer	8.41e-07	2.03e-05	CbGpPWpGaD
Sorafenib—CYP3A5—Metabolism—PTGS2—skin cancer	8.39e-07	2.03e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—TP53—skin cancer	8.34e-07	2.02e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—TP53—skin cancer	8.32e-07	2.01e-05	CbGpPWpGaD
Sorafenib—MAP3K7—Signaling Pathways—IL6—skin cancer	8.05e-07	1.95e-05	CbGpPWpGaD
Sorafenib—KIT—Signaling Pathways—IL6—skin cancer	8.05e-07	1.95e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—KRAS—skin cancer	8.04e-07	1.94e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—HRAS—skin cancer	7.98e-07	1.93e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—HRAS—skin cancer	7.96e-07	1.92e-05	CbGpPWpGaD
Sorafenib—FGFR1—Signaling Pathways—IL6—skin cancer	7.64e-07	1.85e-05	CbGpPWpGaD
Sorafenib—PDGFRA—Signaling Pathways—IL6—skin cancer	7.62e-07	1.84e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—NRAS—skin cancer	7.54e-07	1.82e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—KRAS—skin cancer	7.52e-07	1.82e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—TP53—skin cancer	7.5e-07	1.81e-05	CbGpPWpGaD
Sorafenib—CYP2C8—Metabolism—PTGS2—skin cancer	7.27e-07	1.76e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—HRAS—skin cancer	7.17e-07	1.73e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—TP53—skin cancer	7.15e-07	1.73e-05	CbGpPWpGaD
Sorafenib—PDGFRB—Signaling Pathways—IL6—skin cancer	6.86e-07	1.66e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—HRAS—skin cancer	6.84e-07	1.65e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—TP53—skin cancer	6.68e-07	1.62e-05	CbGpPWpGaD
Sorafenib—HTR2B—Signaling Pathways—IL6—skin cancer	6.54e-07	1.58e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—ERCC2—skin cancer	6.51e-07	1.57e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—KRAS—skin cancer	6.49e-07	1.57e-05	CbGpPWpGaD
Sorafenib—CYP2C19—Metabolism—PTGS2—skin cancer	6.49e-07	1.57e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—HRAS—skin cancer	6.39e-07	1.55e-05	CbGpPWpGaD
Sorafenib—ABCB1—Metabolism—PTGS2—skin cancer	6.33e-07	1.53e-05	CbGpPWpGaD
Sorafenib—RAF1—Signaling Pathways—IL6—skin cancer	6.12e-07	1.48e-05	CbGpPWpGaD
Sorafenib—CYP2D6—Metabolism—PTGS2—skin cancer	5.97e-07	1.44e-05	CbGpPWpGaD
Sorafenib—CYP2C9—Metabolism—PTGS2—skin cancer	5.92e-07	1.43e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—TP53—skin cancer	5.77e-07	1.39e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—HRAS—skin cancer	5.52e-07	1.33e-05	CbGpPWpGaD
Sorafenib—HTR2C—Signaling Pathways—IL6—skin cancer	5.28e-07	1.28e-05	CbGpPWpGaD
Sorafenib—CYP1A2—Metabolism—PTGS2—skin cancer	5.05e-07	1.22e-05	CbGpPWpGaD
Sorafenib—CYP3A4—Metabolism—PTGS2—skin cancer	3.9e-07	9.43e-06	CbGpPWpGaD
